Sarah Alter

1.1k total citations
19 papers, 839 citations indexed

About

Sarah Alter is a scholar working on Immunology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Sarah Alter has authored 19 papers receiving a total of 839 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Immunology, 10 papers in Oncology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Sarah Alter's work include Immune Cell Function and Interaction (16 papers), CAR-T cell therapy research (7 papers) and Immunotherapy and Immune Responses (7 papers). Sarah Alter is often cited by papers focused on Immune Cell Function and Interaction (16 papers), CAR-T cell therapy research (7 papers) and Immunotherapy and Immune Responses (7 papers). Sarah Alter collaborates with scholars based in United States, China and South Korea. Sarah Alter's co-authors include Emily K. Jeng, Hing C. Wong, Jeffrey Schlom, Richard L. Riley, Michelle Ratliff, Bonnie B. Blomberg, Daniela Frasca, Peter R. Rhode, Wenxin Xu and Anna Kwilas and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Sarah Alter

19 papers receiving 818 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sarah Alter United States	11	660	435	83	64	57	19	839
Murielle Corvaisier France	9	732 1.1×	330 0.8×	126 1.5×	23 0.4×	50 0.9×	9	929
Séverine Bézie France	14	580 0.9×	179 0.4×	88 1.1×	46 0.7×	32 0.6×	27	766
Sandrine Buisson France	8	287 0.4×	181 0.4×	53 0.6×	40 0.6×	39 0.7×	8	423
Mélanie Durand France	9	522 0.8×	132 0.3×	197 2.4×	42 0.7×	38 0.7×	10	759
Megan Broadwater United States	5	387 0.6×	291 0.7×	76 0.9×	23 0.4×	44 0.8×	5	574
Hugh H. Reid Australia	9	444 0.7×	73 0.2×	84 1.0×	50 0.8×	99 1.7×	12	667
Julia A. Wagner United States	10	871 1.3×	541 1.2×	130 1.6×	24 0.4×	49 0.9×	20	1.0k
Casimir de Rham Switzerland	10	406 0.6×	136 0.3×	147 1.8×	41 0.6×	98 1.7×	14	658
Eduardo Cuende Spain	13	231 0.3×	78 0.2×	154 1.9×	52 0.8×	63 1.1×	32	590
Tomohisa Nishioka Japan	5	955 1.4×	401 0.9×	58 0.7×	26 0.4×	35 0.6×	7	1.1k

Countries citing papers authored by Sarah Alter

Since Specialization

Citations

This map shows the geographic impact of Sarah Alter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Alter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Alter more than expected).

Fields of papers citing papers by Sarah Alter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Alter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Alter. The network helps show where Sarah Alter may publish in the future.

Co-authorship network of co-authors of Sarah Alter

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Alter. A scholar is included among the top collaborators of Sarah Alter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Alter. Sarah Alter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Furuya, Hideki, Owen Chan, Ian Pagano, et al.. (2019). Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model. Journal of Translational Medicine. 17(1). 29–29. 20 indexed citations

Knudson, Karin M., Kristin C. Hicks, Sarah Alter, Jeffrey Schlom, & Sofia R. Gameiro. (2019). Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy. Journal for ImmunoTherapy of Cancer. 7(1). 82–82. 87 indexed citations

Chu, Yaya, Jeremy Rosenblum, Emily K. Jeng, et al.. (2019). Efficiently Targeting Metastatic Osteosarcoma, Neuroblastoma and Glioblastoma with Ex-Vivo Expanded Natural Killer Cells Combined with N-803 (ALT-803, IL-15 Superagonist) and TIM-3 Blockage. Biology of Blood and Marrow Transplantation. 25(3). S336–S336. 5 indexed citations

Nayyar, Gaurav, Yaya Chu, Emily K. Jeng, et al.. (2019). Combining ROR1- Specific Chimeric Antigen Receptor (CAR) NK Cells with IL-15 Superagonist (N-803/ALT-803) to Target Chemotherapy Resistant Neuroblastoma. Biology of Blood and Marrow Transplantation. 25(3). S334–S334. 1 indexed citations

Edwards, Dorothy Farrar, et al.. (2019). Reliability and Validity of a Functional Cognition Screening Tool to Identify the Need for Occupational Therapy. American Journal of Occupational Therapy. 73(2). 7302205050p1–7302205050p10. 17 indexed citations

Liu, Bai, Monica Jones, Lin Kong, et al.. (2018). Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models. Cytokine. 107. 105–112. 30 indexed citations

Burrack, Kristina S., Matthew A. Huggins, Emily Taras, et al.. (2018). Interleukin-15 Complex Treatment Protects Mice from Cerebral Malaria by Inducing Interleukin-10-Producing Natural Killer Cells. Immunity. 48(4). 760–772.e4. 58 indexed citations

Chu, Yaya, Nang Kham Su, Sarah Alter, et al.. (2017). Therapeutic Effects of a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2B8T2M) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL). Blood. 130. 3587–3587. 1 indexed citations

Liu, Bai, Lin Kong, Kaiping Han, et al.. (2017). Novel antitumor complexes of bispecific antibodies using ALT-803 as a scaffold demonstrate Tetra-specific binding activities. The Journal of Immunology. 198(Supplement_1). 120.12–120.12. 1 indexed citations

10.

Khomtchouk, Kelly, Sarah Alter, Michelle Ratliff, Bonnie B. Blomberg, & Richard L. Riley. (2016). In old BALB/c mice, bone marrow pre-B cell and surrogate light chain reduction is associated with increased B cell reactivity to phosphorylcholine, but reduced T15 idiotype dominance. Mechanisms of Ageing and Development. 162. 53–62. 4 indexed citations

11.

Liu, Bai, Lin Kong, Kaiping Han, et al.. (2016). A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses. Journal of Biological Chemistry. 291(46). 23869–23881. 60 indexed citations

12.

Kim, Peter, Anna Kwilas, Wenxin Xu, et al.. (2016). Abstract 3245: IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity of murine breast and colon carcinomas. Cancer Research. 76(14_Supplement). 3245–3245. 1 indexed citations

13.

Kim, Peter, Anna Kwilas, Wenxin Xu, et al.. (2016). IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. Oncotarget. 7(13). 16130–16145. 135 indexed citations

14.

Rhode, Peter R., Jack O. Egan, Wenxin Xu, et al.. (2015). Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models. Cancer Immunology Research. 4(1). 49–60. 170 indexed citations

15.

Chen, Xiaoyue, Bai Liu, Kaiping Han, et al.. (2015). Combination therapy of an IL-15 superagonist complex, ALT-803, and a tumor targeting monoclonal antibody promotes direct antitumor activity and protective vaccinal effect in a syngenic mouse melanoma model. Journal for ImmunoTherapy of Cancer. 3(Suppl 2). P347–P347. 4 indexed citations

16.

Mathios, Dimitrios, Chul‐Kee Park, Warren D. Marcus, et al.. (2015). Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. International Journal of Cancer. 138(1). 187–194. 84 indexed citations

17.

Ratliff, Michelle, Sarah Alter, Daniela Frasca, et al.. (2015). In aged mice, low surrogate light chain promotes pro‐B‐cell apoptotic resistance, compromises the PreBCR checkpoint, and favors generation of autoreactive, phosphorylcholine‐specific B cells. Aging Cell. 14(3). 382–390. 19 indexed citations

18.

Fishman, Mayer, Daniel A. Vaena, Parminder Singh, et al.. (2015). Phase Ib/II study of an IL-2/T-cell receptor fusion protein in combination with gemcitabine and cisplatin in advanced or metastatic chemo-refractory urothelial cancer (UC).. Journal of Clinical Oncology. 33(15_suppl). 4515–4515. 6 indexed citations

19.

Ratliff, Michelle, Sarah Alter, Daniela Frasca, Bonnie B. Blomberg, & Richard L. Riley. (2013). In senescence, age‐associated B cells secrete TNFα and inhibit survival of B‐cell precursors*. Aging Cell. 12(2). 303–311. 136 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact